Letter to Shareholders End of Year Summary and 2023 Plans

As 2022 draws to a close, I would like to take a moment to extend my most sincere gratitude to each and every one of Amplia Therapeutics’ (ASX:ATX) supporters. We are backed by an enviable network of investors, corporate leaders, clinical and scientific experts, and other stakeholders who are truly invested in our journey. Over the last 12 months, the Amplia team has executed our clinical and busi